KEROS THERAPEUTICS
Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with a high unmet medical need. Keros is a leader in understanding the role of the Transforming Growth Factor-Beta, or TGF-ß, family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros' lead ... protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros' lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from elevated levels of hepcidin, the key regulator of iron absorption and recycling, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros' third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.
KEROS THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2015-01-01
Address:
Lexington, Massachusetts, United States
Country:
United States
Website Url:
http://www.kerostx.com
Total Employee:
11+
Status:
Active
Contact:
(617)513-8774
Total Funding:
90 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Content Delivery Network Euro Microsoft Exchange Online Amazon
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Baudax Bio
Baudax Bio is a specialty pharmaceutical company focused on developing and commercializing innovative products for acute care settings.
Clearside Biomedical
Clearside BioMedical is an ophthalmic company that specializes in the research, development, and commercialization of therapeutic products.
Crinetics Pharmaceuticals
Crinetics is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Lixte Biotechnology Holdings
Lixte Biotechnology Holdings, a clinical-stage pharmaceutical company, focuses on discovering drugs for more effective cancer treatments.
OS Therapies
OS Therapies is a therapeutics company focused on the identification, development, and commercialization of treatments for Osteosarcoma.
Provention Bio
Provention Bio is a clinical stage biopharmaceutical dedicated to sourcing, developing and commercializing novel therapeutics.
Rarecells
Rarecells Inc. is a healthcare company focused on the development and commercialization of non-invasive Early Cancer Detection tests.
Zymenex
Zymenex is a Scandinavian biopharmaceutical company focused on the development and commercialization of novel enzyme replacement therapies
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
OrbiMed
OrbiMed investment in Series C - Keros Therapeutics
Venrock
Venrock investment in Series C - Keros Therapeutics
Medison Pharma
Medison Pharma investment in Series C - Keros Therapeutics
Foresite Capital
Foresite Capital investment in Series C - Keros Therapeutics
Pontifax
Pontifax investment in Series C - Keros Therapeutics
Partners Innovation Fund
Partners Innovation Fund investment in Series C - Keros Therapeutics
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Series C - Keros Therapeutics
Arkin Bio Ventures
Arkin Bio Ventures investment in Series C - Keros Therapeutics
Global health sciences venture fund
Global health sciences venture fund investment in Series C - Keros Therapeutics
Medison Pharma
Medison Pharma investment in Series B - Keros Therapeutics
Key Employee Changes
Date | New article |
---|---|
2022-01-31 | Keros Therapeutics Appoints Christopher Rovaldi as Chief Operating Officer |
Official Site Inspections
http://www.kerostx.com Semrush global rank: 1.05 M Semrush visits lastest month: 31.93 K
- Host name: 120.0.153.160.host.secureserver.net
- IP address: 160.153.0.120
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260

More informations about "Keros Therapeutics"
Investors & Media - Keros Therapeutics
Jun 6, 2025 The Investor Relations website contains information about Keros Therapeutics's business for stockholders, potential investors, and financial analysts.See details»
Keros Therapeutics - LinkedIn
Keros Therapeutics Biotechnology Research Lexington, Massachusetts 7,270 followers Keros is dedicated to the discovery and development of novel therapeutics for multiple disorders.See details»
Keros Therapeutics - Crunchbase Company Profile
Keros is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of novel treatments.See details»
Keros Therapeutics, Inc. (KROS) - Yahoo Finance
See the company profile for Keros Therapeutics, Inc. (KROS) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Keros Therapeutics (KROS) Company Profile & Description
Apr 8, 2020 Company profile for Keros Therapeutics, Inc. (KROS) stock, with a description, list of executives, contact details and other key facts.See details»
Overview, News & Similar companies - ZoomInfo.com
View Keros Therapeutics (www.kerostx.com) location in Massachusetts, United States , revenue, industry and description. Find related and similar companies as well as employees by title and …See details»
Keros Therapeutics - businessabc
Jul 21, 2025 Keros was founded in the fall of 2015 with the mission of making novel, life changing therapies for serious and rare diseases with unmet needs. The company was formed …See details»
Keros Therapeutics Company Overview, Contact Details
Jan 3, 2024 Learn more about Keros Therapeutics's company details, contact information, competitors, and more. Find accurate contact data easily with LeadIQ. Book a demo today.See details»
Keros Therapeutics Reports Recent Business Highlights and Fourth ...
Feb 26, 2025 The increase was primarily due to an increase in personnel expenses to support the Company's organizational growth and achievement of its corporate goals, an increase in …See details»
Keros Therapeutics Announces TROPOS Topline Data and …
May 29, 2025 The Company shared top-line results in a presentation that will be accessible in the Investors section of the Keros website at https://ir.kerostx.com. The Company plans to …See details»
Keros Therapeutics CEO and Key Executive Team - Craft.co
Keros Therapeutics's CEO and Director is Jasbir Seehra. Other executives include Christopher Rovaldi, Chief Operating Officer; Keith Regnante, Chief Financial Officer and 7 others. See the …See details»
Corporate Presentation - Keros Therapeutics
These and other risks are described more fully in Keros’ filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Quarterly Report …See details»
Keros Therapeutics Announces Review of Strategic Alternatives
Apr 10, 2025 Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. …See details»
SEC Filing - Keros Therapeutics - ir.kerostx.com
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1 (e), …See details»
Keros Therapeutics, Inc. (KROS) - Yahoo Finance
Find the latest Keros Therapeutics, Inc. (KROS) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Keros Therapeutics Announces Global License Agreement with …
Dec 3, 2024 Keros Therapeutics to receive upfront payment of $200 million and is eligible to receive development, approval and commercial milestone payments with the potential to …See details»
Keros Reinforces Commitment to Maximizing Stockholder Value
May 8, 2025 Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting “FOR” the Company’s Highly Qualified Director Nominees …See details»
SEC Filing - Keros Therapeutics - ir.kerostx.com
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO …See details»
Keros Therapeutics Highlights Commitment to Maximizing …
May 19, 2025 Files Investor Presentation and Issues Open Letter to Stockholders Urges Stockholders to Protect the Value of Their Investment by Voting “FOR” Each of the Company’s …See details»
Keros to Exclusively Prioritize the Clinical Advancement of KER-065
2 days ago Keros also today announced several Board of Directors (the “Board”) and leadership transitions intended to support the Company’s streamlined vision and operational focus. These …See details»